Showing posts with label Global Mumps Market Value. Show all posts
Showing posts with label Global Mumps Market Value. Show all posts

Friday, August 3, 2018

Global Impact Of Mumps Market Outlook: Ken Research


Mumps is an acute communicable viral disease that passes from one person to another person through saliva, nasal secretions and close personal contact. The mumps virus is an RNA virus. It’s most distinctive symptomsis the inflammation of one or both of the parotid glands. The disease may also affect other salivary glands, gonads (testicles) and the meninges. According to the study, ‘Mumps – Pipeline Review, H2 2018, most people who encounter the virus show symptoms of the disease such as those already mentioned along with headache and fatigue among others. Since mumps is a virus, it does not respond to antibiotics or other medications however, symptoms can be treated to make oneself more comfortable.

The most successful method of tackling mumps was discovered in the late 1950s when the MMR vaccine (measles, mumps and rubella) was introduced in the US and found to be extremely effective as cases declined almost entirely. This soon led to worldwide adoption of the vaccine before which there were epidemics reported every two to five years with winter and spring seeing the greatest number of cases.
Mumps was earlier more prevalent in children whereas today more than half of the cases are observed in young adults. A large number of people in closely knit environments such as schools and military establishments are more susceptible.

However, with modern vaccination available today, mumps is not at all fatal and is similar to a seasonal flu. Many nations have mandated the vaccines for a number of ailments in order to protect the children. In the UK for instance, universal MMR vaccination became standard in 1988 and in 2013 the UK Health and Social Care Information Centre (HSCIC) reported that during 2012-13 more than nine-tenth of the children had been immunized using the MMR vaccine. This was the highest UK MMR vaccination level recorded since its introduction in the UK.

The US on the other hand is facing some problems with mumps as it does not seem to be able to control it. Mumps seems to be making resurgence with cases at a ten-year high and becoming common on college campuses across the country. Recently, the Dallas area saw the largest outbreak in Texas in years with more than fifty cases whereas there have not been more than twenty cases in the entire state in any year since 2011. Seeing this, experts have begun to come up with possible explanations for the state of the USA when it comes to mumps. A resurgence of mumps in the US among vaccinated young adults appears to be due to waning of vaccine-induced immunity, according to a recent analysis. Researchers found vaccine-derived immune protection against mumps lasts about twenty-seven years after the last dose. The findings suggest that, in addition to the currently recommended two doses of mumps vaccine in childhood, a third dose at age eighteen may help sustain protection. Another research conducted in the US revealed the possibility that a large percentage of youth with HIV may lack immunity to measles, mumps and rubella.

Mumps is relatively much less severe today and this is due to mainly the global immunization programs incorporating the use of vaccines such as MMR. This vaccine is still widely used today alongside other symptom specific remedies for mumps. Recently a number of studies conducted in the US have shed new light on the disease and are aimed at explaining resurgences better and for future well being as well.

For more information on the research report, refer to below link:-

Related Reports:-


Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249